An allosteric inhibitor like maraviroc does not bind directly to the connection points of chemokines. It binds deep into the CCR5 receptor and changes the shape of the receptor which doesn't allow some or all of the chemokines to dock.

A competitive inhibitor directly binds to the binding sites that chemokines use blocking them from binding.